SCHEMBL1645586

SCHEMBL1645586

COc1cc(C=O)c(Br)cc1O

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKDC P78527 1/20 0.72
ERN1 O75460 6/20 0.54
ALDH1A1 P00352 4/20 0.52
TDP1 Q9NUW8 2/20 0.52
KDM4E B2RXH2 1/20 0.52
TSHR P16473 1/20 0.52
LMNA P02545 2/20 0.51
BACE1 P56817 1/20 0.51
CGAS Q8N884 4/20 0.50
SIRT1 Q96EB6 1/20 0.49
HPGD P15428 2/20 0.49
MAPT P10636 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
AOX1 Q06278 1/20 0.49
TRIM24 O15164 1/20 0.49
ALDH5A1 P51649 1/20 0.49
ABAT P80404 1/20 0.49
TRIM33 Q9UPN9 1/20 0.49
MEN1 O00255 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1320502 0.93 PRKDC (0.72) PRKDCERN1ALDH1A1TDP1KDM4E
SCHEMBL7410524 0.85 PRKDC (0.61) PRKDCERN1ALDH1A1TDP1KDM4E
SCHEMBL515642 0.84 PRKDC (1.00) PRKDCERN1ALDH1A1TDP1KDM4E
SCHEMBL23094474 0.83 XDH (0.54) PRKDCERN1ALDH1A1TDP1LMNA
SCHEMBL1002368 0.82 ALDH1A1 (0.69) PRKDCERN1ALDH1A1TDP1KDM4E
SCHEMBL1004432 0.82 ALDH1A1 (0.57) PRKDCERN1ALDH1A1TDP1KDM4E
SCHEMBL29459727 0.82 ALDH1A1 (0.69) PRKDCERN1ALDH1A1TDP1KDM4E
SCHEMBL29459687 0.82 ALDH1A1 (0.57) PRKDCERN1ALDH1A1TDP1KDM4E
SCHEMBL698744 0.82 PRKDC (0.81) PRKDCERN1ALDH1A1TDP1KDM4E
SCHEMBL23094682 0.81 LMNA (0.75) PRKDCERN1ALDH1A1KDM4ETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179087-A1 COMPOUNDS AND THEIR USES AS LPAR5 ANTAGONISTS Immunophage Biotech (Shanghai) Co., Ltd. (CN) 2025-06-05 US disclosed
CN-119403800-A Compounds and their use as LPAR5 antagonists 艾美斐生物医药科技(上海)有限公司 2025-02-07 CN disclosed
EP-4486742-A1 COMPOUNDS AND THEIR USES AS LPAR5 ANTAGONISTS IMMUNOPHAGE BIOTECH (SHANGHAI) CO., LTD. (CN) 2025-01-08 EP disclosed
US-20240239787-A1 COMPOUNDS FOR USE IN THE TREATMENT OF CANCER NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2024-07-18 US disclosed
US-20240239787-A1 COMPOUNDS FOR USE IN THE TREATMENT OF CANCER NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2024-07-18 US disclosed
EP-4334294-A1 COMPOUNDS FOR USE IN THE TREATMENT OF CANCER Nanyang Technological University (SG) 2024-03-13 EP disclosed
US-11767286-B2 Phenylpropionate compound, preparation method for same, and applications thereof SUZHOU PHARMAVAN CO., LTD (CN) 2023-09-26 US disclosed
WO-2023165591-A1 COMPOUNDS AND THEIR USES AS LPAR5 ANTAGONISTS IMMUTHER PHARMATECH (SHANGHAI) CO., LTD. (CN) 2023-09-07 WO disclosed
CN-116635371-A Polycyclic pyridazinone derivative serving as SOS1 inhibitor, and preparation method and application thereof 苏州阿尔脉生物科技有限公司 2023-08-22 CN disclosed
CN-116606256-A Benzimidazole-4-carboxamide derivatives with selective PARP-1 inhibition effect 山东大学 2023-08-18 CN disclosed
US-7790896-B2 RNA-selective probes for live cell imaging of nuclear structure and function NEW YORK UNIVERSITY (US) 2010-09-07 US disclosed
US-20100190831-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2010-07-29 US disclosed
US-20100190831-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2010-07-29 US disclosed
WO-2010080537-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2010-07-15 WO disclosed
US-20100048901-A1 NOVEL CURCUMIN DERIVATIVE TOKYO INSTITUTE OF TECHNOLOGY (JP) 2010-02-25 US disclosed
EP-2123637-A1 NOVEL CURCUMIN DERIVATIVE Tokyo Institute of Technology (JP) 2009-11-25 EP disclosed
US-20090111962-A1 Palladium Complexes and Polymerization and Coupling Processes Thereof WEST CHESTER UNIVERSITY OF PENNSYLVANIA OF THE STATE SYSTEM OF HIGHER EDUCATION 2009-04-30 US disclosed
US-20080064037-A1 RNA-SELECTIVE PROBES FOR LIVE CELL IMAGING OF NUCLEAR STRUCTURE AND FUNCTION NEW YORK UNIVERSITY (US) 2008-03-13 US disclosed
US-20080064037-A1 RNA-SELECTIVE PROBES FOR LIVE CELL IMAGING OF NUCLEAR STRUCTURE AND FUNCTION NEW YORK UNIVERSITY (US) 2008-03-13 US disclosed
US-3976695-A Halogen substituted α-(aminoalkyl)-3,4-dihydroxybenzyl alcohols SMITHKLINE CORPORATION (US) 1976-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048901-A1 NOVEL CURCUMIN DERIVATIVE BACE1, APP, BACE2 PRKDC 4869/4885ERN1 2254/4885ALDH1A1 253/4885
US-20080064037-A1 RNA-SELECTIVE PROBES FOR LIVE CELL IMAGING OF NUCLEAR STRUCTURE AND FUNCTION SNRPE, HNRNPUL2, EFTUD2 PRKDC 2754/4885ERN1 157/4885ALDH1A1 4222/4885
US-11767286-B2 Phenylpropionate compound, preparation method for same, and applications thereof PLAT, TFPI, PF4 PRKDC 4436/4885ERN1 4206/4885ALDH1A1 711/4885
US-20100190831-A1 GPR120 RECEPTOR AGONISTS AND USES THEREOF GPR119, GPR52, GCGR PRKDC 4823/4885ERN1 3254/4885ALDH1A1 3347/4885
US-20090111962-A1 Palladium Complexes and Polymerization and Coupling Processes Thereof DDT, PDCD2L, PDCD1LG2 PRKDC 565/4885ERN1 4681/4885ALDH1A1 1671/4885
US-20240239787-A1 COMPOUNDS FOR USE IN THE TREATMENT OF CANCER BRIX1, TP53, XPOT PRKDC 2794/4885ERN1 1051/4885ALDH1A1 1975/4885
US-20250179087-A1 COMPOUNDS AND THEIR USES AS LPAR5 ANTAGONISTS LPAR5, LPAR3, LPAR2 PRKDC 4072/4885ERN1 3850/4885ALDH1A1 2592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.